Arvaya Healthcare Ltd (524723)

Arvaya Healthcare has received in-principle approval from BSE dated October 12, 2026, for a preferential allotment of 38,71,854 equity shares. The shares carry a face value of Rs 10 each and are priced at an issue price of Rs 40 per share, implying a total fundraise of approximately Rs 15.49 crore. This proposed capital infusion equals about 6.2% of the company's current market capitalization of Rs 248 crore and represents about 26.7% of its existing net worth of Rs 58 crore. For a company with negligible TTM revenues (Rs 0 crore) and a TTM net loss of Rs -2 crore, the fresh capital provides liquidity but comes at a steep discount to the current market price of Rs 116.

• Received BSE in-principle approval on October 12, 2026
• Approval granted for preferential issue of 38,71,854 equity shares
• Face value fixed at Rs 10 per equity share
• Issue price set at Rs 40 per share, totaling Rs 15.49 crore

Arvaya Healthcare has issued notice for its 41st Annual General Meeting to be held on September 21, 2026. Key special business includes approval of material related party transactions (RPTs) aggregating up to Rs 370 Crore across 9 promoter, subsidiary, and group entities for FY27. Additionally, the company seeks shareholder approval to acquire intellectual property and copyright assets from DEFIB Institute of Health Solutions LLP (an entity connected to Executive Director Bidari Kotresh Anilkumar) funded through Rights Issue proceeds.

• 41st AGM scheduled for Monday, September 21, 2026 at 3:00 PM via Video Conferencing.
• Shareholder approval sought for FY27 RPT limits totaling Rs 370 Crore across 9 entities, including promoter entities (Rs 40-50 Cr each).
• Proposed acquisition of IP and copyright portfolio from DEFIB Institute of Health Solutions LLP funded out of Rights Issue proceeds.
• Executive Director Bidari Kotresh Anilkumar holds 3.58% in Arvaya and is a Designated Partner in DEFIB.

Arvaya Healthcare's Board has approved the acquisition of the copyright and intellectual property portfolio of DEFIB INSTITUTE OF HEALTH SOLUTIONS LLP for a consideration not exceeding ₹10 crore. The transaction is structured strictly as an IP assignment and will be funded out of the proceeds of the company's Rights Issue. As a Material Related Party Transaction, it is subject to statutory compliance and shareholder approval under SEBI LODR regulations. The board revised the scope during the meeting from a previously planned slump-sale acquisition.

• Acquisition consideration capped at not exceeding ₹10 Crores based on independent valuation
• Funded out of proceeds from the company's Rights Issue
• Structured strictly as an assignment of Copyright and IP portfolio, not a slump sale
• Requires shareholder approval under SEBI LODR Regulation 23 for material related-party transactions

Arvaya Healthcare Ltd has scheduled a Board of Directors meeting on August 26, 2026, to consider and approve a related party transaction. The proposal involves acquiring the business undertaking of Navahmedi Solution Private Limited via a slump sale, encompassing intellectual property, assets, and liabilities. The acquisition is intended to be funded out of rights issue proceeds. Key financial details, including acquisition valuation and transaction consideration, will depend on the outcome of the board meeting.

• Board meeting scheduled for August 26, 2026 to evaluate the transaction.
• Proposed acquisition of business undertaking from Navahmedi Solution Private Limited via slump sale.
• Scope includes transfer of intellectual property, assets, and liabilities.
• Acquisition to be funded utilizing proceeds from the company's rights issue.

Arvaya Healthcare has approved the incorporation of a wholly-owned subsidiary in India to enter the insurance broking service industry. This represents a significant strategic pivot for the company, which reported zero revenue throughout FY26 and the trailing twelve months. The commencement of operations is contingent upon obtaining regulatory approval from the Insurance Regulatory Development Authority of India (IRDA). With a current net worth of ‑‑58 Cr and a market cap of ‑‑143 Cr, the company is attempting to operationalize its business after a period of inactivity.

• 100% ownership of the proposed subsidiary to be held by Arvaya Healthcare Ltd
• Entry into the Insurance Broking sector, moving away from its current dormant trading status
• Mandatory regulatory approval required from IRDA before business commencement
• Company reported Rs 0.0 Cr revenue in the most recent quarter ending March 2026
• Promoter holding has significantly decreased from 62.73% in December 2025 to 30.62% in June 2026

Arvaya Healthcare's Annual Secretarial Compliance Report for FY26 reveals several procedural lapses, including non-adherence to Secretarial Standard-1 regarding the circulation of board minutes and delayed website disclosures. The report confirms that the Board approved the 100% acquisition of three entities—Health Secure Hospitals, Arvaya Health and Wellness, and Tec Pool Solutions—in November 2025. A preferential issue was subsequently approved in March 2026 to fund these acquisitions. These strategic moves come as the company reports zero revenue for the TTM period and a net loss of ₹1.2 Cr for FY26.

• Board approved 100% acquisition of three private entities on November 4, 2025, to pivot the business.
• Preferential issue of equity shares approved on March 4, 2026, as consideration for the acquisitions.
• Auditor noted non-compliance with Secretarial Standard-1 (SS-1) regarding the timely circulation of board meeting minutes.
• Delayed website disclosures under Regulation 46 were attributed to a change in company management during the year.
• Incorrect Scrip Code was used in multiple PDF submissions to the Stock Exchange, leading to disclosure inconsistencies.

Arvaya Healthcare's board has approved material related party transactions (RPTs) totaling ₹370 crore for FY 2026-27 across nine entities, including promoters and subsidiaries. This is highly significant given the company reported zero revenue in FY26 and has a market capitalization of only ₹143 crore. The board also approved the incorporation of a new wholly-owned subsidiary to enter the General and Life Insurance broking business. Additionally, the company approved Q1 FY27 results and scheduled its 41st AGM for September 21, 2026.

• Approved ₹370 crore in total related party transactions for FY 2026-27 across 9 different entities
• Individual RPTs with promoter-linked entities and subsidiaries range from ₹40 crore to ₹50 crore each
• Proposed incorporation of a new Wholly Owned Subsidiary to act as a Direct Insurance Broker
• 41st Annual General Meeting (AGM) scheduled for September 21, 2026
• Reconstituted the Nomination and Remuneration Committee to ensure regulatory compliance

Arvaya Healthcare has approved a massive ₹370 crore in material Related Party Transactions (RPTs) for FY 2026-27 across nine entities, including promoters and subsidiaries. This is highly significant given the company reported zero revenue in FY26 and has a market cap of only ₹143 crore. The board also approved a pivot into the insurance broking business through a new wholly-owned subsidiary. The 41st Annual General Meeting (AGM) is scheduled for September 21, 2026, where shareholders will vote on these RPTs.

• Approved ₹370 crore in Related Party Transactions for FY 2026-27 across 9 different entities
• Proposed incorporation of a new Wholly Owned Subsidiary to act as a Direct Insurance Broker
• Scheduled the 41st Annual General Meeting for September 21, 2026
• Reconstituted the Nomination and Remuneration Committee to fix a compliance gap by replacing an Executive Director with an Independent Director
• Approved the appointment of Mr. Kaushal Shah as Managing Director, liable to retire by rotation

Arvaya Healthcare has scheduled a board meeting for August 12, 2026, to approve its Q1 FY27 results and consider 'material related party transactions.' This is a critical update as the company reported zero revenue throughout FY26 and the preceding four quarters. Investors should note the significant drop in promoter holding from 62.73% in December 2025 to 30.62% in June 2026, despite a 449% stock price surge over the last 12 months. The meeting will also address director appointments for three wholly-owned subsidiaries and finalize the FY26 Annual Report.

• Board meeting scheduled for August 12, 2026, to approve unaudited Q1 results.
• Agenda includes the approval of material related party transactions (RPTs).
• Company reported Rs 0 Cr revenue for the last four consecutive quarters ending March 2026.
• Promoter holding has significantly decreased to 30.62% as of June 2026.
• Board to consider director appointments for subsidiaries including Health Secure Hospitals and Tec-Pool Solutions.